TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3580237
Drug: Midazolam given
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam given as hourly intermittent injections
Study: 3580237
Drug: Midazolam (infusion)
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam (infusion)
Study: 20577748
Drug: Letrozole (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (2.5 mg daily for 5 days for up to six cycles)
Study: 16520208
Drug: Continuous enhanced
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous enhanced circulation therapy (CECT) system combined with low-dose aspirin (100 mg daily postoperatively)
Study: 16520208
Drug: Enoxaparin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (40 mg per day)
Study: 14743970
Drug: Colon-targeted tablets
Normalized name: Sus scrofa colon preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colon-targeted tablets of metronidazole
Study: 14743970
Drug: Immediate release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release tablets of metronidazole
Study: 7549809
Drug: Smokers and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smokers and patients with oral leukoplakia or erythroplakia
Study: 7549809
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with oral trauma
Study: 7022275
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release metoprolol 200 mg once daily
Study: 7022275
Drug: Conventional formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional formulation metoprolol 100 mg bd
Study: 31416685
Drug: Radiotherapy (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy (70 Gy, with chemotherapy if N1-2)
Study: 28886024
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) 25 mg/day with metformin (MET) 2 g/day for 3 months
Study: 28886024
Drug: Placebo (Plac)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Plac) with metformin (MET) 2 g/day for 3 months
Study: 25845992
Drug: nab-paclitaxel 40
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab-paclitaxel 40 mg/m² and carboplatin AUC 2 with concurrent radiotherapy 66 Gy in 33 fractions
Study: 25845992
Drug: nab-paclitaxel 60
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab-paclitaxel 60 mg/m² and carboplatin AUC 2 with concurrent radiotherapy 66 Gy in 33 fractions
Study: 25845992
Drug: nab-paclitaxel 40
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab-paclitaxel 40 mg/m²
Study: 23453583
Drug: Tosedostat 120
Normalized name: Tosedostat
DrugBank: Tosedostat (DB11781)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tosedostat 120 mg once daily for 6 months
Study: 23453583
Drug: Tosedostat 240
Normalized name: Tosedostat
DrugBank: Tosedostat (DB11781)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tosedostat 240 mg once daily for 2 months followed by 120 mg for 4 months
Study: 20187484
Drug: Restrictive protocol
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive protocol for intravenous fluid administration (group A, 65 pts)
Study: 20187484
Drug: Liberal fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liberal fluid administration policy (group B, 65 pts)
Study: 11348960
Drug: 10-mL/kg loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-mL/kg loading dose of perflubron
Study: 11348960
Drug: 20-mL/kg loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-mL/kg loading dose of perflubron
Study: 9205821
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of JTP-4819 30 mg
Study: 9205821
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of JTP-4819 60 mg
Study: 9205821
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of JTP-4819 120 mg
Study: 9205821
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of JTP-4819 60 mg three times daily for 7 days
Study: 9205821
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of JTP-4819 60 mg
Study: 9205821
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of JTP-4819
Study: 9205821
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of JTP-4819
Study: 2885827
Drug: Almitrine-raubasine combination
Normalized name: almitrine
DrugBank: Almitrine (DB01430)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrine-raubasine combination
Study: 29573167
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with transcranial pulsed electromagnetic fields (T-PEMFs), 30 minutes daily for eight consecutive weeks.
Study: 29573167
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with T-PEMFs.
Study: 27194717
Drug: Intravenous alanyl-glutamine
Normalized name: Alanyl glutamine
DrugBank: Alanyl glutamine (DB11876)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous alanyl-glutamine (0.5 g·kg(‐1)·day(‐1))
Study: 29352829
Drug: No supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: No supplement (control group)
Study: 25635977
Drug: Telmisartan (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan (40 mg a day)
Study: 21120597
Drug: Media system
Normalized name: Stellaria media extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Media system A (G-IVF (TM) v5 PLUS/ G-1(TM) v5 PLUS)
Study: 16533195
Drug: Prolotherapy injections
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolotherapy injections and exercises
Study: 3326634
Drug: Propranolol, 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol, 80 mg three times daily
Study: 6191137
Drug: Metoprolol, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol, 100 mg two times daily
Study: 6191137
Drug: Control, without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control, without concurrent drugs
Study: 30782343
Drug: Lomustine-temozolomide therapy
Normalized name: Lomustine
DrugBank: Lomustine (DB01206)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lomustine-temozolomide therapy (100 mg/m2 on day 1 plus temozolomide 100–200 mg/m2 per day on days 2–6 of the 6-week course)
Study: 30782343
Drug: Standard temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard temozolomide therapy (75 mg/m2 per day concomitant to radiotherapy followed by six courses of temozolomide 150–200 mg/m2 per day on the first 5 days of the 4-week course)
Study: 30782343
Drug: Lomustine-temozolomide therapy
Normalized name: Lomustine
DrugBank: Lomustine (DB01206)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lomustine-temozolomide therapy
Study: 30782343
Drug: Standard temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard temozolomide therapy
Study: 12766388
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin patches (20 mg/24 h) administered intermittently
Study: 12766388
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin patches (20 mg/24 h) administered continuously
Study: 9831410
Drug: Ondansetron 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 8 mg tds
Study: 809046
Drug: Briserin (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Briserin (0.1 mg reserpine, 5 mg clopamide, 0.5 mg dihydroergocristin/per tablet)
Study: 30930609
Drug: Cognitive Behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavior Therapy (CBT) with trauma-focused emotion regulation skills (TARGET)
Study: 30930609
Drug: Cognitive Behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavior Therapy (CBT) without trauma-focused emotion regulation skills
Study: 18259100
Drug: Intravenous alfacalcidol
Normalized name: alfacalcidol
DrugBank: Alfacalcidol (DB01436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous alfacalcidol (mean dose 3.63 +/- 1.71 microg/week)
Study: 14635746
Drug: Hedrocel implants
Normalized name: acetaminophen / hydrocodone bitartrate Oral Capsule [Hydrocet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hedrocel implants with autologous cancellous bone graft
Study: 14635746
Drug: Solid block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solid block implant
Study: 12196612
Drug: Training intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training intervention for injection drug users to serve as peer mentors
Study: 9385614
Drug: Clomipramine (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine (12.5 mg, intravenous, single dose)
Study: 7878638
Drug: Methacholine (Mch)
DrugBank: Methacholine (DB06709)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methacholine (Mch) infusion (0.1‐0.8‐4.0 micrograms/min)
Study: 7878638
Drug: Sodium nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sodium nitroprusside (SNP) infusion (0.5‐2.5‐10 micrograms/min)
Study: 7878638
Drug: Pre-infusion baseline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-infusion baseline
Study: 3225660
Drug: Weaning at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weaning at 1700 g
Study: 30337189
Drug: Weaning at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weaning at 1800 g
Study: 3225660
Drug: Weaning at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weaning at 1700 g (birth weight ≤ 1000 g)
Study: 31584739
Drug: AZD9977 (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD9977 (50, 150, and 300 mg, twice daily for 8 days)
Study: 28668251
Drug: Bicycle train
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicycle train intervention (daily cycling with study staff to and from school)
Study: 23616506
Drug: Whole walnuts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole walnuts (85 g)
Study: 23616506
Drug: Nut skins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nut skins (5.6 g)
Study: 23616506
Drug: Nut oil
Normalized name: Peanut Oil
DrugBank: Peanut oil (DB13964)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nut oil (51 g)
Study: 23616506
Drug: De-fatted nutmeat
Normalized name: sangre de grado
Approvals — FDA: no, EMA: no, PMDA: no
Description: De-fatted nutmeat (34 g)
Study: 29772695
Drug: BoNT‐A injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: BoNT‐A injections
Study: 15020604
Drug: AAWD and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: AAWD and ketoconazole (400 mg orally tid)
Study: 15020604
Drug: Deferred treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred treatment with ketoconazole
Study: 11278149
Drug: Physostigmine; specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine; specific dosage and duration not mentioned
Study: 9727818
Drug: Phenylpropanolamine (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylpropanolamine (12.5 mg)
Study: 9727818
Drug: Phenylpropanolamine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylpropanolamine (25 mg)
Study: 9727818
Drug: Methylphenidate (5
Normalized name: methylphenidate (50/50 release) 20 mg/24 hr oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (5 mg)
Study: 9727818
Drug: Midodrine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midodrine (5 mg)
Study: 31077667
Drug: Hydrogen (H2)
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrogen (H2) dissolved in irrigation solution
Study: 31077667
Drug: Conventional solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional solution (Control)
Study: 22254118
Drug: Spirulina (19
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirulina (19 g daily)
Study: 22254118
Drug: Soybean (19
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soybean (19 g daily)
Study: 10329858
Drug: Estring (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estring (2 mg estradiol)
Study: 7498565
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Pilocarpine 4% and Phenylephrine 10% drops
Study: 1685945
Drug: loratadine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: loratadine (10 mg daily)
Study: 1685945
Drug: beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: beclomethasone dipropionate (100 micrograms in each nostril twice daily)
Study: 7390386
Drug: Lipo-Merz retard
Normalized name: diclofenac sodium Extended Release Oral Tablet [Lofensaid Retard]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipo-Merz retard (1 capsule/day)
Study: 7390386
Drug: Commercial combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial combination product (1 capsule three times daily)
Study: 30521757
Drug: Solriamfetol 37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solriamfetol 37.5 mg
Study: 30521757
Drug: Solriamfetol (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solriamfetol (all doses except 37.5 mg)
Study: 27427786
Drug: Recombinant activated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant activated factor VII (rFVIIa) at a dosage of 90 μg/kg, administered in one to three doses for joint bleeding treatment.
Study: 27427786
Drug: Self-administered additional
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered additional haemostatic medication (AHM) up to 48 hours after the first rFVIIa treatment.
Study: 27427786
Drug: Time to
Normalized name: Overtime Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time to treatment initiation.
Study: 21597261
Drug: Terazosin 2
Normalized name: terazosin 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terazosin 2 mg (once nightly) for 4 weeks
Study: 21852581
Drug: Ramipril (ACE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (ACE inhibitor)
Study: 12510249
Drug: Losartan (Angiotensin-receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (Angiotensin-receptor antagonist)
Study: 1401438
Drug: Fluoride gel
Normalized name: Sodium Fluoride Gel
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride gel (FG; 1.1% NaF)
Study: 31256094
Drug: Versatile physiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Versatile physiotherapy intervention conducted in accordance with European Physiotherapy Guideline for Parkinson's Disease (EPGPD), 16 one-hour therapy sessions (twice per week) over 10 weeks.
Study: 26517202
Drug: Aripiprazole lauroxil
Normalized name: Aripiprazole lauroxil
DrugBank: Aripiprazole lauroxil (DB14185)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aripiprazole lauroxil (both doses)
Study: 20219294
Drug: delayed-treatment control
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: delayed-treatment control condition
Study: 19030203
Drug: Pantoprazole (PPI)
DrugBank: Pantoprazole (DB00213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pantoprazole (PPI) treatment
Study: 19030203
Drug: Primary care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary care treatment (not according to study protocol)
Study: 16037177
Drug: Intrathecal clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal clonidine (300 microg in 2 mL)
Study: 12067088
Drug: CM acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: CM acupuncture (real treatment)
Study: 12067088
Drug: Sham acupuncture
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham acupuncture (control treatment)
Study: 12067088
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (real and sham)
Study: 8879853
Drug: Single large
Normalized name: Bos taurus large intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single large i.v. dose of gentamicin (10 mg/kg)
Study: 8879853
Drug: Standard multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard multiple dose regimen of gentamicin (2.5 mg/kg i.v. stat and then divided doses)
Study: 1638335
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg vitamin C
Study: 6542082
Drug: Methylphenidate (dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (dosage titrated based on augmenter-reducer classification and pretreatment HR levels)
Study: 29769026
Drug: CareWell program
Approvals — FDA: no, EMA: no, PMDA: no
Description: CareWell program (multidisciplinary team meetings, proactive care planning, case management, medication reviews)
Study: 27349717
Drug: Combination oral
Normalized name: PROBIOTIC COMBINATION ORAL CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination oral care (tooth brushing, chlorhexidine, and cold water)
Study: 27349717
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard oral care regimen)
Study: 10827812
Drug: Rifaximin suspension
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifaximin suspension 1800 mg three times a day plus Omeprazole 20 mg twice a day (n = 10)
Study: 10827812
Drug: Rifaximin pills
Normalized name: rifaximin Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin pills 1800 mg three times a day plus Omeprazole twice a day (n = 10)
Study: 10827812
Drug: Rifaximin suspension
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifaximin suspension
Study: 10827812
Drug: Rifaximin pills
Normalized name: rifaximin Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin pills
Study: 1810681
Drug: Atenolol, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol, a beta 1‐selective adrenergic blocker, administered for an unspecified duration.
Study: 24222260
Drug: Clonidine (200-μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (200-μg initially, then 100-μg due to side effects)
Study: 19161059
Drug: Intensive individual
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive individual tooth brushing training every three months and guidance on oral health.
Study: 16080073
Drug: Tigecycline (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tigecycline (initial dose of 100 mg, followed by 50 mg intravenously every 12 h)
Study: 16080073
Drug: Imipenem-cilastatin (500/500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem-cilastatin (500/500 mg intravenously every 6 h)
Study: 9498728
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg Naltrexone (NTX)
Study: 9098273
Drug: 0.5% timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% timolol applied twice daily
Study: 375342
Drug: BAY g
Normalized name: ALCOHOL 70 L in 100 L TOPICAL GEL [Victoria Bay Gel Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY g 5421 (Acarbose) 75 mg
Study: 375342
Drug: BAY g
Normalized name: ALCOHOL 70 L in 100 L TOPICAL GEL [Victoria Bay Gel Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY g 5421 (Acarbose) 150 mg
Study: 375342
Drug: BAY g
Normalized name: ALCOHOL 70 L in 100 L TOPICAL GEL [Victoria Bay Gel Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY g 5421 (Acarbose) 300 mg
Study: 375342
Drug: BAY g
Normalized name: ALCOHOL 70 L in 100 L TOPICAL GEL [Victoria Bay Gel Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY g 5421 (Acarbose)
Study: 31856945
Drug: 4-session smoking
Normalized name: TOBACCO SMOKE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-session smoking cessation treatment
Study: 25607226
Drug: Intravenous caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous caffeine citrate (20 mg/kg) before 2 hours of age
Study: 14702024
Drug: Independent evaluators'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Independent evaluators' guesses about treatment condition during post-treatment assessments
Study: 8050210
Drug: Subcutaneous (SC)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) erythropoietin (EPO) at a dose of 120 iu/kg/week
Study: 8050210
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) erythropoietin (EPO) at a dose of 120 iu/kg/week
Study: 8050210
Drug: Subcutaneous (SC)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) EPO
Study: 8050210
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) EPO
Study: 8050210
Drug: Subcutaneous (SC)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) EPO and Intravenous (IV) EPO
Study: 3391624
Drug: Oxytetracycline and
Normalized name: Oxytetracycline and Nystatin Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytetracycline and pyridostigmine in combination
Study: 28215611
Drug: Prolotherapy injection
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolotherapy injection (n=60)